The market for diabetes-management technology has shifted from basic, isolated devices to integrated, software-driven systems. Today, patient care relies on automated insulin delivery (AID) loops that link continuous glucose monitors (CGMs) with smart insulin pumps via specialized control algorithms. For medical device procurement officers, hospital value analysis committees (VACs), regulatory affairs leads, and medtech competitive-intelligence analysts, understanding the structure of the manufacturing base behind these systems is critical for supply-chain resilience and regulatory planning.
To map the registration landscape of this sector, we conducted a reproducible analysis of the U.S. Food and Drug Administration's (FDA) Global Unique Device Identification Database (GUDID). Managed in partnership with the National Library of Medicine (NLM), GUDID stores the static Device Identifier (DI) portion of the Unique Device Identifier (UDI) required on all medical device labels.
Our analysis scanned the complete GUDID registry of 5,083,948 unique device records (mirroring the baseline of our broad FDA-registered device establishments by country study) to isolate a specific cohort of 4,151 diabetes-management device identifier records. The data reveals a landscape characterized by extreme SKU concentration, where raw DI counts are heavily dominated by the manufacturers of high-volume infusion-set consumables rather than the makers of the electronic pump and sensor systems.
How many insulin-pump and CGM device identifiers are in the FDA GUDID database?
Of the 5.08 million device records registered in the FDA GUDID database, our analysis identified 4,151 unique diabetes-management device identifiers. Under the FDA's UDI rule, a unique DI is assigned to every individual physical catalog model and packaging variant registered by a device labeler. Therefore, this count represents the total volume of distinct product configurations (SKUs) registered for the U.S. market, rather than units sold or patients treated.
Sub-Cohort Distribution within the Diabetes Device Registry
We segmented the 4,151-record cohort by device category using a keyword-matching query over the brand names and device descriptions. Because a single GUDID record can list characteristics that fall into multiple categories (for instance, a combined closed-loop system kit that includes both pump components and sensor transmitters), the sub-cohort counts represent overlapping bounds:
- Insulin Pump / Infusion Consumables: 2,429 device identifiers (58.5% of the cohort)
- Blood Glucose Meters (BGM) & Test Strips: 1,306 device identifiers (31.5%)
- Insulin Pens (Traditional & Smart): 343 device identifiers (8.3%)
- Continuous Glucose Monitor (CGM) Sensors/Transmitters: 122 device identifiers (2.9%)
- Automated Insulin Delivery (AID) / Closed-Loop Systems: 60 device identifiers (1.4%)
The massive share occupied by the insulin pump/infusion sub-cohort (2,429 DIs) immediately highlights the operational footprint of insulin delivery. Traditional syringe-based or pen-based delivery yields relatively few GUDID records, whereas insulin pumps require a vast ecosystem of sterile disposables—including infusion sets, tubing variants, cannulas, and reservoirs—each of which requires its own unique UDI barcode.
Which manufacturers hold the most diabetes-device DI records?
To map the competitive structure of the registry, we aggregated the 4,151 diabetes-device DIs by the registered labeler (brand owner). The table below ranks the top 25 companies by their total device-identifier counts in the GUDID database:
| Rank | Registered Company Name (GUDID Labeler) | GUDID Device Identifiers (DIs) | Share of Cohort (%) | Primary Portfolio Focus |
|---|---|---|---|---|
| 1 | Unomedical A/S | 561 | 13.5% | Infusion set consumables (OEM) |
| 2 | SB-Kawasumi Laboratories, Inc. | 194 | 4.7% | Infusion set consumables (OEM) |
| 3 | BD Switzerland Sàrl | 186 | 4.5% | Pen needles, insulin syringes |
| 4 | Trividia Health, Inc. | 120 | 2.9% | Blood glucose meters, test strips |
| 5 | Vygon Corporation | 118 | 2.8% | Specialized infusion lines, connectors |
| 6 | Norfolk Medical | 92 | 2.2% | Vascular access ports, specialized lines |
| 7 | Abbott Diabetes Care Inc | 76 | 1.8% | FreeStyle Libre CGM, glucose meters |
| 8 | Tandem Diabetes Care, Inc. | 75 | 1.8% | t:slim X2 insulin pump, reservoirs |
| 9 | MediVena, LLC | 75 | 1.8% | Safety lancets, pen needles |
| 10 | HMD Biomedical Inc. | 72 | 1.7% | Blood glucose meters, test strips |
| 11 | Ascensia Diabetes Care US Inc. | 70 | 1.7% | Contour glucose meters, Eversense CGM |
| 12 | Berpu Medical Technology Co., Ltd. | 70 | 1.7% | Insulin syringes, pen needles |
| 13 | CME America LLC | 68 | 1.6% | Ambulatory infusion pumps |
| 14 | Welldoc, Inc. | 68 | 1.6% | Software-as-a-medical-device (SAMD) |
| 15 | Arkray USA, Inc. | 67 | 1.6% | Blood glucose meters, test strips |
| 16 | Home Aide Diagnostics, Inc. | 65 | 1.6% | Glucose monitoring systems |
| 17 | Jiangsu Caina Medical Co., Ltd. | 59 | 1.4% | Syringes, safety pen needles |
| 18 | Tyson Bioresearch Inc. | 55 | 1.3% | Blood glucose systems |
| 19 | LifeScan Europe GmbH | 54 | 1.3% | OneTouch glucose meters, test strips |
| 20 | Fora Care Inc. | 53 | 1.3% | Multi-functional monitoring systems |
| 21 | Promisemed Medical Devices Inc. | 51 | 1.2% | Pen needles, insulin syringes |
| 22 | All-Med Inc | 51 | 1.2% | Sterile disposable supplies |
| 23 | Promisemed Hangzhou Meditech Co., Ltd. | 50 | 1.2% | Pen needles, insulin syringes |
| 24 | Leventon Sau | 46 | 1.1% | Elastomeric infusion pumps |
| 25 | Shenzhen Yuwen E-Commerce Co., Ltd. | 45 | 1.1% | Distributed private-label components |
Why do infusion-set consumables dominate the DI count over pump-system OEMs?
For supply-chain managers and procurement leads, a key insight from this GUDID database analysis is the consumable SKU sprawl. Looking at the top ranks, the database is dominated by companies that patients rarely interact with directly:
- Unomedical A/S (561 DIs): Unomedical (a subsidiary of Convatec) is the leading contract manufacturer of insulin infusion sets globally. It manufactures infusion sets for major pump OEMs, including Medtronic, Tandem, and Roche. Because Unomedical registers hundreds of distinct physical configurations—varying by cannula material (teflon vs. steel), cannula length (6mm to 9mm), tubing length (23 inches to 43 inches), insertion angle (90-degree straight vs. 30-degree angled), and connector type (luer-lock vs. proprietary t:lock)—it holds a massive GUDID registry footprint that dwarfs the actual pump system manufacturers.
- SB-Kawasumi Laboratories (194 DIs): SB-Kawasumi is another major medical supplier of specialized infusion administration sets and plastic medical components. It registers extensive catalog variations of sterile infusion accessories.
- BD Switzerland Sàrl (186 DIs): Becton Dickinson holds a leading position in traditional insulin delivery. Its footprint is driven by different gauge and length configurations of pen needles and piston syringes.
In contrast, the actual original equipment manufacturers (OEMs) of the smart pump systems sit significantly lower in DI count:
- Tandem Diabetes Care (75 DIs): Tandem registers the t:slim X2 pump, the Mobi pump, and the associated cartridge reservoirs. Because the hardware itself has only a few active model configurations, its GUDID footprint is relatively small.
- Abbott Diabetes Care (76 DIs): Abbott's Libres have a small GUDID footprint because the continuous sensor is sold as a unified, single-model construct with a fixed operational life.
For clinical value analysis committees, this highlights a critical structural gotcha: a manufacturer's GUDID DI count does not correlate with their market share or commercial revenue. A company with a dominant market share (such as Abbott in CGMs) may register fewer than 80 DIs, while an OEM contract supplier of plastic tubes (such as Unomedical) registers over 500.
The Mechanics of Infusion Set SKU Sprawl
The physical construction of infusion sets explains this extreme SKU proliferation. To accommodate different patient anatomies (pediatric vs. adult, lean vs. high body fat) and clinical needs, manufacturers must register distinct variants:
- Cannula Materials: Teflon (soft, flexible plastic) is comfortable but prone to kinking or occlusion; steel cannulas are rigid, preventing kinks, but must be replaced more frequently and can cause discomfort. Each material requires a separate UDI registration.
- Insertion Angles: 90-degree straight inserters are standard; 30-degree angled inserters are used for lean patients or those with active lifestyles.
- Connector Interfaces: Historically, standard luer-lock connectors allowed cross-brand compatibility. Today, pump manufacturers utilize proprietary connectors (such as Tandem's t:lock or Medtronic's proprietary connector) to enforce closed ecosystems, requiring separate registrations for each connector type.
- Packaging Tiers: Every packaging configuration (single unit, box of 10, case of 100) must have a unique Device Identifier (DI) under the FDA UDI rule, multiplying the registration count for every physical product variant.
Which FDA product codes (LZG, QFG, FPA) drive the diabetes-device cohort?
The FDA classifies medical devices under three-letter product codes that map each Device Identifier to a regulatory classification. To map the technical diversity of the cohort, we extracted and aggregated the product codes listed in the GUDID registrations. One methodological caveat matters here: FDA product codes are broad regulatory buckets, not diabetes-specific categories. A single code such as FPA ("Set, Administration, Intravascular") is a generic intravenous-administration code, and insulin infusion sets registered under it inherit that code. The table below lists the top 20 FDA product codes in the diabetes-device cohort using each code's official FDA classification name:
| Rank | FDA Product Code | GUDID Count | Regulatory Class | Official FDA Device Classification Name | Diabetes-Specific? |
|---|---|---|---|---|---|
| 1 | FPA | 1,539 | Class II | Set, Administration, Intravascular | No (generic administration sets, incl. insulin infusion sets) |
| 2 | NBW | 1,031 | Class II | System, Test, Blood Glucose, Over The Counter | Yes (OTC blood glucose meters & strips) |
| 3 | FMI | 406 | Class II | Needle, Hypodermic, Single Lumen | No (generic hypodermic needle) |
| 4 | CGA | 354 | Class II | Glucose Oxidase, Glucose | Partial (blood-glucose test chemistry reagent) |
| 5 | LFR | 295 | Class II | Glucose Dehydrogenase, Glucose | Partial (blood-glucose test chemistry reagent) |
| 6 | FRN | 168 | Class II | Pump, Infusion | No (generic infusion pump) |
| 7 | FMF | 149 | Class II | Syringe, Piston | No (generic piston syringe) |
| 8 | JJX | 140 | Class I | Single (Specified) Analyte Controls | No (laboratory quality-control material) |
| 9 | LHI | 105 | Class II | Set, I.V. Fluid Transfer | No (IV fluid transfer set) |
| 10 | MEB | 87 | Class II | Pump, Infusion, Elastomeric | No (elastomeric infusion pump) |
| 11 | NDC | 56 | Class II | Calculator, Drug Dose | Partial (drug-dose calculation software) |
| 12 | LZG | 55 | Class II | Pump, Infusion, Insulin | Yes (traditional insulin pump) |
| 13 | PTI | 50 | Class II | Non-Coring (Huber) Needle | No (implanted-port access needle) |
| 14 | MRZ | 50 | Class II | Accessories, Pump, Infusion | No (generic infusion pump accessories) |
| 15 | QFG | 43 | Class II | Alternate Controller Enabled Insulin Infusion Pump | Yes (ACE insulin infusion pump) |
| 16 | FOX | 37 | Class I | Stand, Infusion | No (IV stand) |
| 17 | OYC | 28 | Class III | Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor | Yes (closed-loop insulin pump with invasive sensor) |
| 18 | JKA | 23 | Class II | Tubes, Vials, Systems, Serum Separators, Blood Collection | No (blood-collection tubes) |
| 19 | FMK | 23 | Class II | Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature | Yes (safety blood lancet) |
| 20 | FOZ | 21 | Class II | Catheter, Intravascular, Therapeutic, Short-Term Less Than 30 Days | No (intravascular catheter) |
Only five of the top 20 codes — NBW, LZG, QFG, OYC, and FMK — are diabetes-specific device classifications in their own right. The remaining 15 are generic infusion, injection, blood-collection, and laboratory codes that sweep up diabetes consumables alongside products used across many other therapies. This is the structural reason a raw product-code count cannot be read as a diabetes-device market map.
The Evolution of Insulin Pump Product Codes
The product-code distribution reflects the regulatory evolution of insulin delivery. Traditional ambulatory insulin pumps are registered under LZG ("Pump, Infusion, Insulin"; 55 DIs) or the broader generic infusion-pump code FRN ("Pump, Infusion"; 168 DIs). As insulin delivery became interoperable and software-driven, the FDA established more specific codes:
- QFG — Alternate Controller Enabled (ACE) Insulin Infusion Pump (43 DIs): This classification covers interoperable insulin pumps designed to receive automated dosing commands from a separate, compatible controller or app, such as Tandem's t:slim X2 (running Control-IQ) or Insulet's Omnipod 5.
- OYC — Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (28 DIs, Class III): This higher-risk classification covers insulin pumps engineered to operate with an invasive (implanted) glucose sensor — the hardware foundation of fully closed-loop systems.
- AID Control Algorithms: The dosing software itself is registered separately under interoperable glycemic-controller codes such as QJI ("Interoperable Automated Glycemic Controller") and QJS ("…Insulin Suspend"), which sit outside the top 20 because each algorithm version generates only a handful of DIs.
For hospital supply chain teams, the practical point is that the small diabetes-specific code footprint — LZG, QFG, and OYC combined total only about 126 DIs — is dwarfed by the generic consumable codes, which is exactly why a DI-count ranking and a market-share ranking look nothing alike. For details on tracking the safety profiles of these device classes, see our guide on drug delivery device adverse events by the numbers and drug delivery device recalls by the numbers for infusion pumps.
How does the GUDID UDI landscape differ from revenue-based market share?
For biopharma executives and market analysts, it is critical to distinguish between the GUDID database footprint and the actual commercial market share of diabetes technology. In the U.S. market, commercial revenue and patient enrollment are highly consolidated, but GUDID records tell a very different story.
The table below contrasts the commercial market share leaders (based on 2026 market data, tracking an estimated $8.2 billion global insulin pump market) with their GUDID device-identifier footprints:
| Device Manufacturer | Estimated US Market Share (2026) | GUDID DI Count | GUDID Cohort Rank | Primary Portfolio Driver |
|---|---|---|---|---|
| Abbott Diabetes Care | ~50% (CGM Market Share) | 76 | 7 | FreeStyle Libre 2/3 sensors |
| Insulet Corporation | ~40% (Insulin Pump Market Share) | 32 | Outside Top 25 | Omnipod system & disposable pods |
| Medtronic Minimed | ~25% (Insulin Pump Market Share) | 38 | Outside Top 25 | MiniMed 780G, Quick-set sets |
| Tandem Diabetes Care | ~25% (Insulin Pump Market Share) | 75 | 8 | t:slim X2, Mobi, AutoSoft sets |
| Dexcom, Inc. | ~45% (CGM Market Share) | 12 | Outside Top 25 | G6/G7 sensors and transmitters |
Explaining the Dexcom and Insulet Database Anomalies
- The Dexcom Absence: Dexcom is one of the top two continuous glucose monitoring manufacturers globally, yet it does not appear in the top 25 GUDID list, holding only 12 unique DIs. This is a result of a private-labeling effect and product architecture. Dexcom manufactures sensors but frequently distributes them through third-party durable medical equipment (DME) channels, or registers them under consolidated international entities. Furthermore, because a Dexcom CGM system consists of a single sensor model and a reusable transmitter that lasts several months, they require very few distinct catalog SKUs compared to a manufacturer of needle-based syringes.
- Insulet's Compact Footprint: Insulet manufactures the Omnipod, a patch pump system that is entirely disposable. Because each pod is self-contained and pre-assembled, Insulet does not need to register hundreds of distinct tubing lengths, needle gauges, or connector adapters, keeping its GUDID DI count (32) small despite having a massive commercial volume of disposable units sold.
What is the AID/closed-loop device footprint in the registry?
Automated Insulin Delivery (AID) systems—frequently referred to as hybrid closed-loop systems or "artificial pancreas" systems—represent the active technological frontier of diabetes care. In the GUDID database, these systems have a relatively small footprint: 60 unique device identifiers (1.4% of the cohort).
This small footprint is driven by two factors:
- Software-as-a-Medical-Device (SaMD): The core intelligence of an AID system is the control algorithm. If the algorithm is delivered via an app on the patient's smartphone, it is registered as a software-only device under dedicated interoperable glycemic-controller codes such as QJI (Interoperable Automated Glycemic Controller) and QJS (…Insulin Suspend), rather than under a hardware pump code. The software does not require physical variants (different lengths or gauges), meaning a single GUDID record can represent millions of software downloads.
- Product Bundling: When manufacturers package an AID system, they register the complete kit as a single parent UDI (for example, a Tandem t:slim X2 pump bundled with a CGM sensor and the Control-IQ software). The individual components are registered separately, but the system kit itself generates only one DI.
For procurement committees and supply chain leads, this highlights the shift toward digital health. When evaluating an AID system, the physical hardware is only one component; the tracking of software version updates, compatibility matrices, and digital licensing agreements represents the new operational reality of diabetes-device management. To see how these pre-market registrations compare to FDA clearance throughput, read our FDA device clearances and approvals by the numbers (2026) report.
Operational Best Practices for Healthcare Supply Chains and Value Analysis Committees
Managing the massive SKU diversity of diabetes consumables represents a major logistical challenge for hospital networks, specialized diabetes centers, and pharmacy benefit managers (PBMs). To optimize supply chain operations and minimize post-market safety risks, healthcare procurement leads should implement three core operational protocols:
1. Catalog Standardization and SKU Consolidation
Because contract manufacturers like Unomedical register hundreds of tubing, cannula, and angle configurations, hospitals frequently suffer from "catalog bloat." Value analysis committees should standardize on a restricted formulary of infusion sets, consolidating contract volumes with a select few vendors. This consolidation increases purchasing leverage, reduces warehouse storage footprint, and simplifies clinical training for nursing staff who teach patients how to insert and manage their infusion sets.
2. Barcode Integration at Point of Care
To ensure patient safety and capture accurate clinical billing, healthcare networks must integrate GUDID device identifiers into their electronic health records (EHR). When a patient is admitted to a hospital with an active insulin pump or AID system, nursing staff should scan the UDI barcode on the pump and any replacement consumables (infusion sets, reservoirs) at the bedside. This automatically logs the manufacturer, model, lot number, and serial number directly to the patient's record, creating a digital trace that is essential for billing charge-capture and clinical safety audits.
3. Automated Safety Recall Triage
The high complexity of Class II ambulatory infusion pumps and disposable sets makes them susceptible to manufacturing defects and safety recalls. If the FDA issues a Class I safety alert (cross-reference our FDA Class I medical device recalls by the numbers (2026) tracker), having bedside UDI scanning implemented allows the hospital's clinical risk team to instantly query the EHR database. The team can identify every patient currently utilizing the affected device identifier or lot number, transforming what was historically a weeks-long manual file audit into a minutes-long database query.
FAQs
Does holding more GUDID device identifiers mean a larger diabetes-device market share?
No. GUDID device-identifier counts measure the diversity of a manufacturer's catalog (SKU variety), not their commercial sales volume or market share. A company that makes contract-manufactured plastic parts (like Unomedical A/S with 561 DIs) holds a large GUDID footprint because they must register every single tubing length, needle gauge, and connector variant. In contrast, a company that dominates the continuous glucose monitoring market (like Dexcom with 12 DIs) holds a small GUDID footprint because their product is highly standardized and has few physical packaging variants.
Which companies make the FDA-registered insulin pump systems vs the infusion-set consumables?
While patients buy insulin pump systems from OEMs like Medtronic, Tandem, and Insulet, the disposable infusion sets are frequently manufactured by third-party contract manufacturers. For example, Unomedical A/S (a division of Convatec) is the primary manufacturer of the plastic infusion sets sold by Medtronic, Tandem, and Roche. Consequently, Unomedical registers these sets under its own name in the GUDID database, making it the largest registrant in the diabetes-device cohort.
Why are CGM sensors undercounted in a keyword-based GUDID scan?
CGM systems generate relatively few GUDID records because they are highly standardized:
- Minimal Physical Variants: A CGM sensor has one needle length and one transmitter shape, requiring only a single DI per generation (e.g., one DI for Dexcom G7). In contrast, an infusion set has dozens of length and angle combinations, generating dozens of DIs.
- Distribution Channels: CGM systems are frequently distributed through pharmacy channels under private-label or distributor listings, which sweeps their registrations under generic distributor names rather than the OEM manufacturer.
What is the difference between a device identifier (DI) and a unique model?
A Device Identifier (DI) is the static portion of a Unique Device Identifier (UDI) barcode that corresponds to a specific packaging level and catalog variant of a device. For example, a single insulin pump model will have one DI for the pump itself, a different DI for a box of 5 pumps, and a different DI for a case of 50 pumps. Therefore, a single "unique model" of an insulin pump can generate multiple DI records in the GUDID database, reflecting the packaging configurations managed in the supply chain.
How do software updates affect AID GUDID registrations?
When a manufacturer updates the control algorithm of an automated insulin delivery (AID) system (for example, releasing a new software version that integrates a new CGM sensor), the update may require a new regulatory registration. If the software is classified as a distinct medical device variant (SaMD), the manufacturer will register a new Device Identifier (DI) in the GUDID database to track the updated version, allowing supply chain and regulatory teams to trace which algorithm generation is active in the field.
Sources
- U.S. Food and Drug Administration (FDA) / National Library of Medicine (NLM). AccessGUDID Unique Device Identification Database. AccessGUDID Portal
- U.S. Food and Drug Administration (FDA). Product Code Classification Database. (Definitions for product codes FPA, NBW, FMI, CGA, LZG, QFG, MRZ). FDA Product Classification
- Fortune Business Insights. Insulin Pump Market Size, Share & Industry Analysis (2026: $8.2 Billion US Market). Fortune Business Insights Report
- Future Market Insights. Continuous Glucose Monitoring (CGM) Systems Market: Competitive Analysis and Tracker. Future Market Insights
- Expert Market Research. Top Insulin Pumps Companies and Manufacturers in the Global Market (2026). EMR Medtech Tracker
